Fibroblast growth factor receptor-like 1

Protein found in humans

FGFRL1

Identifiers
Aliases| FGFRL1, FGFR5, FHFR, fibroblast growth factor receptor-like 1, fibroblast growth factor receptor like 1, FGFR-5
External IDs| OMIM: 605830; MGI: 2150920; HomoloGene: 11067; GeneCards: FGFRL1; OMA:FGFRL1 - orthologs
| Gene location (Human)

Chr.| Chromosome 4 (human)[1]

Band| 4p16.3| Start| 1,009,936 bp[1]
End| 1,026,898 bp[1]
| Gene location (Mouse)

Chr.| Chromosome 5 (mouse)[2]

Band| 5|5 F| Start| 108,840,248 bp[2]
End| 108,854,790 bp[2]
| RNA expression pattern

Bgee| | Human| Mouse (ortholog)

|

| Top expressed in

* right uterine tube

* left lobe of thyroid gland

* right lobe of thyroid gland

* body of pancreas

* Descending thoracic aorta

* ascending aorta

* left adrenal gland

* left adrenal cortex

* right adrenal gland

* right adrenal cortex

| Top expressed in

* basilar part of occipital bone

* larynx

* Paneth cell

* laryngeal cartilages

* ascending aorta

* thumb

* aortic valve

* index finger

* white adipose tissue

* phalanx of index finger

More reference expression data
BioGPS| |

More reference expression data
| Gene ontology

Molecular function|

* fibroblast growth factor binding
* heparin binding
* fibroblast growth factor-activated receptor activity

Cellular component|

* integral component of membrane
* Golgi apparatus
* transport vesicle
* cell-cell contact zone
* membrane
* plasma membrane

Biological process|

* skeletal system development
* ventricular septum morphogenesis
* cell-cell adhesion via plasma-membrane adhesion molecules
* substrate adhesion-dependent cell spreading
* protein homooligomerization
* heart valve morphogenesis
* protein heterooligomerization
* diaphragm development
* negative regulation of cell population proliferation
* fibroblast growth factor receptor signaling pathway

Sources:Amigo / QuickGO
| Orthologs

Species| Human| Mouse
Entrez| |

53834

116701

Ensembl| |

ENSG00000127418

ENSMUSG00000008090

UniProt| |

Q8N441

Q91V87

RefSeq (mRNA)| |

NM_001004356
NM_001004358
NM_021923
NM_001370296
NM_017862

NM_001164259
NM_054071

RefSeq (protein)| |

NP_001004356
NP_001004358
NP_068742
NP_001357225
NP_001004356.1

NP_001157731
NP_473412

Location (UCSC)| Chr 4: 1.01 – 1.03 Mb| Chr 5: 108.84 – 108.85 Mb
PubMed search| [3]| [4]
Wikidata
| View/Edit Human| View/Edit Mouse

|

Fibroblast growth factor receptor-like 1 is a protein that in humans is encoded by the FGFRL1 gene.[5]

The protein encoded by this gene is a member of the fibroblast growth factor receptor (FGFR) family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. A marked difference between this gene product and the other family members is its lack of a cytoplasmic tyrosine kinase domain. The result is a transmembrane receptor that could interact with other family members and potentially inhibit signaling. Multiple alternatively spliced transcript variants encoding the same isoform have been found for this gene.[5]

Transgenic mice expressing the giraffe ortholog of FGFRL1 are resistant against hypertension induced by angiotensin II.[6]

## References

[edit]

1. ^ a b c GRCh38: Ensembl release 89: ENSG00000127418 - Ensembl, May 2017
2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000008090 - Ensembl, May 2017
3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. ^ a b "Entrez Gene: FGFRL1 fibroblast growth factor receptor-like 1".
6. ^ Liu C, Gao J, Cui X, Li Z, Chen L, Yuan Y, Zhang Y, Mei L, Zhao L, Cai D, Hu M, Zhou B, Li Z, Qin T, Si H, Li G, Lin Z, Xu Y, Zhu C, Yin Y, Zhang C, Xu W, Li Q, Wang K, Gilbert MT, Heller R, Wang W, Huang J, Qiu Q (March 2021). "A towering genome: Experimentally validated adaptations to high blood pressure and extreme stature in the giraffe". Science Advances. 7 (12). Bibcode:2021SciA....7.9459L. doi:10.1126/sciadv.abe9459. PMC 7968835. PMID 33731352.

## Further reading

[edit]

* Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–174\. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.1–2&rft.pages=171-174&rft.date=1994-01&rft_id=info:doi/10.1016/0378-1119(94)90802-8&rft_id=info:pmid/8125298&rft.aulast=Maruyama&rft.aufirst=K&rft.au=Sugano,+S&rfr_id=info:sid/en.wikipedia.org:Fibroblast+growth+factor+receptor-like+1" class="Z3988">
* Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–156\. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.1–2&rft.pages=149-156&rft.date=1997-10&rft_id=info:doi/10.1016/S0378-1119(97)00411-3&rft_id=info:pmid/9373149&rft.aulast=Suzuki&rft.aufirst=Y&rft.au=Yoshitomo-Nakagawa,+K&rft.au=Maruyama,+K&rft.au=Suyama,+A&rft.au=Sugano,+S&rfr_id=info:sid/en.wikipedia.org:Fibroblast+growth+factor+receptor-like+1" class="Z3988">
* Wiedemann M, Trueb B (October 2000). "Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors". Genomics. 69 (2): 275–279\. doi:10.1006/geno.2000.6332. PMID 11031111.
* Kim I, Moon S, Yu K, Kim U, Koh GY (March 2001). "A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas(1)". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1518 (1–2): 152–156\. doi:10.1016/s0167-4781(00)00282-7. PMID 11267671.1–2&rft.pages=152-156&rft.date=2001-03&rft_id=info:doi/10.1016/s0167-4781(00)00282-7&rft_id=info:pmid/11267671&rft.aulast=Kim&rft.aufirst=I&rft.au=Moon,+S&rft.au=Yu,+K&rft.au=Kim,+U&rft.au=Koh,+GY&rfr_id=info:sid/en.wikipedia.org:Fibroblast+growth+factor+receptor-like+1" class="Z3988">
* Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG (June 2001). "Identification of a new fibroblast growth factor receptor, FGFR5". Gene. 271 (2): 171–182\. doi:10.1016/S0378-1119(01)00518-2. PMID 11418238.
* Trueb B, Zhuang L, Taeschler S, Wiedemann M (September 2003). "Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues". The Journal of Biological Chemistry. 278 (36): 33857–33865\. doi:10.1074/jbc.M300281200. PMID 12813049.
* Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A (October 2003). "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Genome Research. 13 (10): 2265–2270\. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309.
* Zhang Z, Henzel WJ (October 2004). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Science. 13 (10): 2819–2824\. doi:10.1110/ps.04682504. PMC 2286551. PMID 15340161.
* Antoine M, Wirz W, Tag CG, Mavituna M, Emans N, Korff T, Stoldt V, Gressner AM, Kiefer P (June 2005). "Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells". Growth Factors. 23 (2): 87–95\. doi:10.1080/08977190500096004. PMID 16019430. S2CID 27380246.
* Schild C, Trueb B (December 2005). "Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors". International Journal of Molecular Medicine. 16 (6): 1169–1173\. doi:10.3892/ijmm.16.6.1169. PMID 16273302.

* v
* t
* e

Growth factor receptor modulators

Angiopoietin|

* Agonists: Angiopoietin 1
* Angiopoietin 4

* Antagonists: Angiopoietin 2
* Angiopoietin 3

* Kinase inhibitors: Altiratinib
* CE-245677
* Rebastinib

* Antibodies: Evinacumab (against angiopoietin 3)
* Nesvacumab (against angiopoietin 2)

CNTF|

* Agonists: Axokine
* CNTF
* Dapiclermin

EGF (ErbB)|

| EGF
(ErbB1/HER1)|

* Agonists: Amphiregulin
* Betacellulin
* EGF (urogastrone)
* Epigen
* Epiregulin
* Heparin-binding EGF-like growth factor (HB-EGF)
* Murodermin
* Nepidermin
* Transforming growth factor alpha (TGFα)

* Kinase inhibitors: Afatinib
* Agerafenib
* Brigatinib
* Canertinib
* Dacomitinib
* Erlotinib
* Gefitinib
* Grandinin
* Icotinib
* Lapatinib
* Neratinib
* Osimertinib
* Vandetanib
* WHI-P 154

* Antibodies: Cetuximab
* Depatuxizumab
* Depatuxizumab mafodotin
* Futuximab
* Imgatuzumab
* Matuzumab
* Necitumumab
* Nimotuzumab
* Panitumumab
* Zalutumumab

|

ErbB2/HER2|

* Agonists: Unknown/none

* Antibodies: Ertumaxomab
* Pertuzumab
* Trastuzumab
* Trastuzumab deruxtecan
* Trastuzumab duocarmazine
* Trastuzumab emtansine

* Kinase inhibitors: Afatinib
* Lapatinib
* Mubritinib
* Neratinib
* Tucatinib

ErbB3/HER3|

* Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))

* Antibodies: Duligotumab
* Patritumab
* Seribantumab

ErbB4/HER4|

* Agonists: Betacellulin
* Epigen
* Heparin-binding EGF-like growth factor (HB-EGF)
* Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))

FGF|

| FGFR1|

* Agonists: Ersofermin
* FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
* Repifermin
* Selpercatinib
* Trafermin
* Velafermin

|

FGFR2|

* Agonists: Ersofermin
* FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)
* Palifermin
* Repifermin
* Selpercatinib
* Sprifermin
* Trafermin

* Antibodies: Aprutumab
* Aprutumab ixadotin

* Kinase inhibitors: Infigratinib

FGFR3|

* Agonists: Ersofermin
* FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)
* Selpercatinib
* Sprifermin
* Trafermin

* Antibodies: Burosumab (against FGF23)

FGFR4|

* Agonists: Ersofermin
* FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)
* Trafermin

Unsorted|

* Agonists: FGF15/19

HGF (c-Met)|

* Agonists: Fosgonimeton
* Hepatocyte growth factor

* Potentiators: Dihexa (PNB-0408)

* Kinase inhibitors: Altiratinib
* AM7
* AMG-458
* Amuvatinib
* BMS-777607
* Cabozantinib
* Capmatinib
* Crizotinib
* Foretinib
* Golvatinib
* INCB28060
* JNJ-38877605
* K252a
* MK-2461
* PF-04217903
* PF-2341066
* PHA-665752
* SU-11274
* Tivantinib
* Volitinib

* Antibodies: Emibetuzumab
* Ficlatuzumab
* Flanvotumab
* Onartuzumab
* Rilotumumab
* Telisotuzumab
* Telisotuzumab vedotin

IGF|

| IGF-1|

* Agonists: des(1-3)IGF-1
* Insulin-like growth factor-1 (somatomedin C)
* IGF-1 LR3
* Insulin-like growth factor-2 (somatomedin A)
* Insulin
* Mecasermin
* Mecasermin rinfabate

* Kinase inhibitors: BMS-754807
* Linsitinib
* NVP-ADW742
* NVP-AEW541
* OSl-906

* Antibodies: AVE-1642
* Cixutumumab
* Dalotuzumab
* Figitumumab
* Ganitumab
* Robatumumab
* R1507
* Teprotumumab
* Xentuzumab (against IGF-1 and IGF-2)

|

IGF-2|

* Agonists: Insulin-like growth factor-2 (somatomedin A)

* Antibodies: Dusigitumab
* Xentuzumab (against IGF-1 and IGF-2)

Others|

* Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7)

* Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
* Trofinetide

LNGF (p75NTR)|

* Agonists: BDNF
* BNN-20
* BNN-27
* Cenegermin
* DHEA
* DHEA-S
* NGF
* NT-3
* NT-4

* Antagonists: ALE-0540
* Dexamethasone
* EVT-901 (SAR-127963)
* Testosterone

* Antibodies: Against NGF: ABT-110 (PG110)
* ASP-6294
* Fasinumab
* Frunevetmab
* Fulranumab
* MEDI-578
* Ranevetmab
* Tanezumab

* Aptamers: Against NGF: RBM-004

* Decoy receptors: LEVI-04 (p75NTR-Fc)

PDGF|

* Agonists: Becaplermin
* Platelet-derived growth factor (A, B, C, D)

* Kinase inhibitors: Agerafenib
* Avapritinib
* Axitinib
* Crenolanib
* Imatinib
* Lenvatinib
* Masitinib
* Motesanib
* Nintedanib
* Pazopanib
* Radotinib
* Quizartinib
* Ripretinib
* Sunitinib
* Sorafenib
* Toceranib

* Antibodies: Olaratumab
* Ramucirumab
* Tovetumab

RET (GFL)|

| GFRα1|

* Agonists: Glial cell line-derived neurotrophic factor (GDNF)
* Liatermin

* Kinase inhibitors: Vandetanib

|

GFRα2|

* Agonists: Neurturin (NRTN)

* Kinase inhibitors: Vandetanib

GFRα3|

* Agonists: Artemin (ARTN)

* Kinase inhibitors: Vandetanib

GFRα4|

* Agonists: Persephin (PSPN)

* Kinase inhibitors: Vandetanib

Unsorted|

* Kinase inhibitors: Agerafenib

SCF (c-Kit)|

* Agonists: Ancestim
* Stem cell factor

* Kinase inhibitors: Agerafenib
* Axitinib
* Dasatinib
* Imatinib
* Masitinib
* Nilotinib
* Pazopanib
* Quizartinib
* Sorafenib
* Sunitinib
* Toceranib

TGFβ|

* See here instead.

Trk|

| TrkA|

* Agonists: Amitriptyline
* BNN-20
* BNN-27
* Cenegermin
* DHEA
* DHEA-S
* Gambogic amide
* NGF
* Tavilermide

* Antagonists: ALE-0540
* Dexamethasone
* FX007
* Testosterone

* Negative allosteric modulators: VM-902A

* Kinase inhibitors: Altiratinib
* AZD-6918
* CE-245677
* CH-7057288
* DS-6051
* Entrectinib
* GZ-389988
* K252a
* Larotrectinib
* Lestaurtinib
* Milciclib
* ONO-4474
* ONO-5390556
* PLX-7486
* Rebastinib
* SNA-120 (pegylated K252a))

* Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110)
* ASP-6294
* Fasinumab
* Frunevetmab
* Fulranumab
* MEDI-578
* Ranevetmab
* Tanezumab

* Aptamers: Against NGF: RBM-004

* Decoy receptors: ReN-1820 (TrkAd5)

|

TrkB|

* Agonists: 3,7-DHF
* 3,7,8,2'-THF
* 4'-DMA-7,8-DHF
* 7,3'-DHF
* 7,8-DHF
* 7,8,2'-THF
* 7,8,3'-THF
* Amitriptyline
* BDNF
* BNN-20
* Deoxygedunin
* Deprenyl
* Diosmetin
* DMAQ-B1
* HIOC
* LM22A-4
* N-Acetylserotonin
* NT-3
* NT-4
* Norwogonin (5,7,8-THF)
* R7
* R13
* TDP6

* Antagonists: ANA-12
* Cyclotraxin B
* Gossypetin (3,5,7,8,3',4'-HHF)

* Ligands: DHEA

* Kinase inhibitors: Altiratinib
* AZD-6918
* CE-245677
* CH-7057288
* DS-6051
* Entrectinib
* GZ-389988
* K252a
* Larotrectinib
* Lestaurtinib
* ONO-4474
* ONO-5390556
* PLX-7486

TrkC|

* Agonists: BNN-20
* DHEA
* NT-3

* Kinase inhibitors: Altiratinib
* AZD-6918
* CE-245677
* CH-7057288
* DS-6051
* Entrectinib
* GZ-389988
* K252a
* Larotrectinib
* Lestaurtinib
* ONO-4474
* ONO-5390556
* PLX-7486

VEGF|

* Agonists: Placental growth factor (PGF)
* Ripretinib
* Telbermin
* VEGF (A, B, C, D (FIGF))

* Allosteric modulators: Cyclotraxin B

* Kinase inhibitors: Agerafenib
* Altiratinib
* Axitinib
* Cabozantinib
* Cediranib
* Fruquintinib
* Lapatinib
* Lenvatinib
* Motesanib
* Nintedanib
* Pazopanib
* Pegaptanib
* Rebastinib
* Regorafenib
* Semaxanib
* Sorafenib
* Sunitinib
* Toceranib
* Tivozanib
* Vandetanib
* WHI-P 154

* Antibodies: Alacizumab pegol
* Bevacizumab
* Icrucumab
* Ramucirumab
* Ranibizumab

* Decoy receptors: Aflibercept

Others|

* Additional growth factors: Adrenomedullin
* Colony-stimulating factors (see here instead)
* Connective tissue growth factor (CTGF)
* Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
* Erythropoietin (see here instead)
* Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
* Glia maturation factor (GMF)
* Hepatoma-derived growth factor (HDGF)
* Interleukins/T-cell growth factors (see here instead)
* Leukemia inhibitory factor (LIF)
* Macrophage-stimulating protein (MSP; HLP, HGFLP)
* Midkine (NEGF2)
* Migration-stimulating factor (MSF; PRG4)
* Oncomodulin
* Pituitary adenylate cyclase-activating peptide (PACAP)
* Pleiotrophin
* Renalase
* Thrombopoietin (see here instead)
* Wnt signaling proteins

* Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)

This article on a gene on human chromosome 4 is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template